Elan (NYS: ELN) reported earnings on Feb. 8. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended Dec. 31 (Q4), Elan missed estimates on revenues and missed expectations on earnings per share.
Compared to the prior-year quarter, revenue contracted, and GAAP loss per share grew.
Margins dropped across the board.
Elan reported revenue of $271.0 million. The five analysts polled by S&P Capital IQ expected a top line of $286.3 million. GAAP sales were 12% lower than the prior-year quarter's $308.9 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Non-GAAP EPS came in at -$0.07. The four earnings estimates compiled by S&P Capital IQ predicted $0.02 per share on the same basis. GAAP EPS were -$0.23 for Q4 compared to -$0.12 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 45.6%, 360 basis points worse than the prior-year quarter. Operating margin was -2.0%, 1,000 basis points worse than the prior-year quarter. Net margin was -49.7%, 2,830 basis points worse than the prior-year quarter.
Next quarter's average estimate for revenue is $296.2 million. On the bottom line, the average EPS estimate is $0.03.
Next year's average estimate for revenue is $1.28 billion. The average EPS estimate is $0.15.
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 904 members rating the stock outperform and 72 members rating it underperform. Among 188 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 175 give Elan a green thumbs-up, and 13 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Elan is outperform, with an average price target of $12.47.
The drug and healthcare investing landscape is littered with also-rans and a few major winners. Is Elan the right stock for you? Read "Discover the Next Rule-Breaking Multibagger" to learn about a company David Gardner believes will be a phenomenal success over the next few years. Click here for instant access to this free report.
Add Elan to My Watchlist.
At the time thisarticle was published Seth Jayson owned shares of the following at the time of publication: Elan. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.